Yarrow Bioscience annual free cash flow
2015
2016
2017
2018
2019
2020
2021
2023
2024
2025
Yarrow Bioscience Free Cash Flow (FCF) History (YARW)
Yarrow Bioscience reported −$33.1M in free cash flow for fiscal 2025, an increase of $965,000 from the previous fiscal year, with a free cash flow margin of −5811.23%.
View full Yarrow Bioscience company overviewYarrow Bioscience free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$33.1M | $965,000 | — | −5811.23% |
| 2024 | 2024-12-31 | −$34.1M | −$8.7M | — | −6804.19% |
| 2023 | 2023-12-31 | −$25.3M | $31.0M | — | −5976.65% |
| 2021 | 2021-12-31 | −$56.4M | $80.8M | — | −6054.46% |
| 2020 | 2020-12-31 | −$137.2M | −$62.7M | — | −653.53% |
| 2019 | 2019-12-31 | −$74.5M | −$5.2M | — | −16806.32% |
| 2018 | 2018-12-31 | −$69.2M | −$41.0M | — | −1925.76% |
| 2017 | 2017-12-31 | −$28.2M | −$26.0M | — | −616.52% |
| 2016 | 2016-12-31 | −$2.3M | $1.9M | — | −340.65% |
| 2015 | 2015-12-31 | −$4.2M | — | — | — |
Yarrow Bioscience quarterly free cash flow
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2021 | 2021-12-31 | −$10.0M | $15.4M | — | −3669.60% |
| Q3 2021 | 2021-09-30 | −$17.5M | $6.1M | — | −13188.72% |
| Q2 2021 | 2021-06-30 | −$16.3M | $19.7M | — | −5510.85% |
| Q1 2021 | 2021-03-31 | −$12.6M | $39.7M | — | −5456.96% |
| Q4 2020 | 2020-12-31 | −$25.4M | −$2.9M | — | −592.04% |
| Q3 2020 | 2020-09-30 | −$23.6M | −$1.4M | — | −723.07% |
| Q2 2020 | 2020-06-30 | −$35.9M | −$22.9M | — | −307.41% |
| Q1 2020 | 2020-03-31 | −$52.3M | −$35.5M | — | −2985.89% |
| Q4 2019 | 2019-12-31 | −$22.4M | — | — | −16624.44% |
| Q3 2019 | 2019-09-30 | −$22.2M | — | — | — |
| Q2 2019 | 2019-06-30 | −$13.0M | — | — | — |
| Q1 2019 | 2019-03-31 | −$16.8M | — | — | −5448.05% |
Yarrow Bioscience free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$74.5M to −$33.1M, a net increase of $41.3M. Yarrow Bioscience's latest reported quarter, Q4 2021, generated −$10.0M in free cash flow, an increase of $15.4M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Yarrow Bioscience filings at SEC.gov ↗